New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report

A 22-year-old male with a history of ulcerative colitis and nephrotic syndrome treated with immunomodulatory agents including vedolizumab and mycophenolic acid developed hyperthyroidism 2 weeks following the first administration of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 vaccine). Graves’ disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Manta, Ringo, Martin, Charlotte, Muls, Vinciane, Poppe, Kris G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346333/
https://www.ncbi.nlm.nih.gov/pubmed/35900872
http://dx.doi.org/10.1530/ETJ-22-0049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346333/
https://www.ncbi.nlm.nih.gov/pubmed/35900872
http://dx.doi.org/10.1530/ETJ-22-0049

Ejemplares similares